APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting DPP-4 Inhibitor Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Long-acting DPP-4 Inhibitor Drug Industry Research Report 2026

27 December 2025117 pages

Choose your research edition.

Industry ResearchLong-acting DPP-4 Inhibitor Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting DPP-4 Inhibitor Drug Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Long-acting DPP-4 Inhibitor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting DPP-4 Inhibitor Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting DPP-4 Inhibitor Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Long-acting DPP-4 Inhibitor Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Long-acting DPP-4 Inhibitor Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Long-acting DPP-4 Inhibitor Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Long-acting DPP-4 Inhibitor Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Long-acting DPP-4 Inhibitor Drug include Easton Biopharmaceuticals, Takeda Pharmaceutical, Merck & Co, Kelun Pharmaceutical, Haisco Pharmaceutical, Beacon Pharma, Baiji Dichang Pharmaceutical and Furiex, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Long-acting DPP-4 Inhibitor Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Long-acting DPP-4 Inhibitor Drug.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Long-acting DPP-4 Inhibitor Drug Market by Company

Easton Biopharmaceuticals

Takeda Pharmaceutical

Merck & Co

Kelun Pharmaceutical

Haisco Pharmaceutical

Beacon Pharma

Baiji Dichang Pharmaceutical

Furiex

Long-acting DPP-4 Inhibitor Drug Segment by Type

Weekly

Biweekly

Long-acting DPP-4 Inhibitor Drug Segment by Application

Hospital

Clinic

Others

Long-acting DPP-4 Inhibitor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting DPP-4 Inhibitor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting DPP-4 Inhibitor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting DPP-4 Inhibitor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Long-acting DPP-4 Inhibitor Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Long-acting DPP-4 Inhibitor Drug Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Type (2021-2026) Table 7. Global Long-acting DPP-4 Inhibitor Drug Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Type (2027-2032) Table 9. Global Long-acting DPP-4 Inhibitor Drug Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Application (2021-2026) Table 11. Global Long-acting DPP-4 Inhibitor Drug Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Application (2027-2032) Table 13. Global Long-acting DPP-4 Inhibitor Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Long-acting DPP-4 Inhibitor Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Long-acting DPP-4 Inhibitor Drug Market Share by Region (2021-2026) Table 16. Global Long-acting DPP-4 Inhibitor Drug Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Long-acting DPP-4 Inhibitor Drug Market Share by Region (2027-2032) Table 18. Long-acting DPP-4 Inhibitor Drug Industry Trends Table 19. Long-acting DPP-4 Inhibitor Drug Industry Drivers Table 20. Long-acting DPP-4 Inhibitor Drug Industry Opportunities and Challenges Table 21. Long-acting DPP-4 Inhibitor Drug Market Restraints Table 22. Global Top Long-acting DPP-4 Inhibitor Drug Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Players (2021-2026) Table 24. Global Long-acting DPP-4 Inhibitor Drug Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Long-acting DPP-4 Inhibitor Drug, Headquarters and Area Served Table 26. Global Long-acting DPP-4 Inhibitor Drug Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Long-acting DPP-4 Inhibitor Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Long-acting DPP-4 Inhibitor Drug Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Long-acting DPP-4 Inhibitor Drug Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Long-acting DPP-4 Inhibitor Drug Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Long-acting DPP-4 Inhibitor Drug Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Size by Country (2027-2032) & (US$ Million) Table 45. Easton Biopharmaceuticals Company Information Table 46. Easton Biopharmaceuticals Business Overview Table 47. Easton Biopharmaceuticals Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) & (US$ Million) Table 48. Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 49. Easton Biopharmaceuticals Recent Developments Table 50. Takeda Pharmaceutical Company Information Table 51. Takeda Pharmaceutical Business Overview Table 52. Takeda Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) & (US$ Million) Table 53. Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 54. Takeda Pharmaceutical Recent Developments Table 55. Merck & Co Company Information Table 56. Merck & Co Business Overview Table 57. Merck & Co Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) & (US$ Million) Table 58. Merck & Co Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 59. Merck & Co Recent Developments Table 60. Kelun Pharmaceutical Company Information Table 61. Kelun Pharmaceutical Business Overview Table 62. Kelun Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) & (US$ Million) Table 63. Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 64. Kelun Pharmaceutical Recent Developments Table 65. Haisco Pharmaceutical Company Information Table 66. Haisco Pharmaceutical Business Overview Table 67. Haisco Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) & (US$ Million) Table 68. Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 69. Haisco Pharmaceutical Recent Developments Table 70. Beacon Pharma Company Information Table 71. Beacon Pharma Business Overview Table 72. Beacon Pharma Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) & (US$ Million) Table 73. Beacon Pharma Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 74. Beacon Pharma Recent Developments Table 75. Baiji Dichang Pharmaceutical Company Information Table 76. Baiji Dichang Pharmaceutical Business Overview Table 77. Baiji Dichang Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) & (US$ Million) Table 78. Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 79. Baiji Dichang Pharmaceutical Recent Developments Table 80. Furiex Company Information Table 81. Furiex Business Overview Table 82. Furiex Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) & (US$ Million) Table 83. Furiex Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 84. Furiex Recent Developments Table 85. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Long-acting DPP-4 Inhibitor Drug Product Image Figure 5. Global Long-acting DPP-4 Inhibitor Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Long-acting DPP-4 Inhibitor Drug Market Share by Type: 2025 VS 2032 Figure 7. Weekly Product Figure 8. Biweekly Product Figure 9. Global Long-acting DPP-4 Inhibitor Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Long-acting DPP-4 Inhibitor Drug Market Share by Application: 2025 VS 2032 Figure 11. Hospital Product Figure 12. Clinic Product Figure 13. Others Product Figure 14. Global Long-acting DPP-4 Inhibitor Drug Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 15. Global Long-acting DPP-4 Inhibitor Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Long-acting DPP-4 Inhibitor Drug Market Share by Region: 2025 VS 2032 Figure 17. Global Long-acting DPP-4 Inhibitor Drug Market Share by Players in 2025 Figure 18. Global Long-acting DPP-4 Inhibitor Drug Manufacturers Established Date Figure 19. Global Top 5 and 10 Long-acting DPP-4 Inhibitor Drug Players Market Share by Revenue in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. North America Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Long-acting DPP-4 Inhibitor Drug Market Share by Country (2021-2032) Figure 23. United States Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Canada Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Mexico Long-acting DPP-4 Inhibitor Drug Market Share by Country (2021-2032) Figure 26. Europe Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Europe Long-acting DPP-4 Inhibitor Drug Market Share by Country (2021-2032) Figure 28. Germany Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. France Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. U.K. Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Italy Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Spain Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Russia Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Netherlands Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Nordic Countries Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Share by Country (2021-2032) Figure 38. China Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Japan Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. South Korea Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Long-acting DPP-4 Inhibitor Drug Market Share by Country (2021-2032) Figure 43. Australia Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. China Taiwan Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Southeast Asia Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Long-acting DPP-4 Inhibitor Drug Market Share by Country (2021-2032) Figure 48. Brazil Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Argentina Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Chile Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Colombia Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Peru Long-acting DPP-4 Inhibitor Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Easton Biopharmaceuticals Revenue Growth Rate in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) Figure 54. Takeda Pharmaceutical Revenue Growth Rate in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) Figure 55. Merck & Co Revenue Growth Rate in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) Figure 56. Kelun Pharmaceutical Revenue Growth Rate in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) Figure 57. Haisco Pharmaceutical Revenue Growth Rate in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) Figure 58. Beacon Pharma Revenue Growth Rate in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) Figure 59. Baiji Dichang Pharmaceutical Revenue Growth Rate in Long-acting DPP-4 Inhibitor Drug Business (2021-2026) Figure 60. Furiex Revenue Growth Rate in Long-acting DPP-4 Inhibitor Drug Business (2021-2026)

Scope & coverage.

Types
  • Weekly
  • Biweekly
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Easton Biopharmaceuticals
  • Takeda Pharmaceutical
  • Merck & Co
  • Kelun Pharmaceutical
  • Haisco Pharmaceutical
  • Beacon Pharma
  • Baiji Dichang Pharmaceutical
  • Furiex

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Long-acting DPP-4 Inhibitor Drug by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Weekly
  5. 2.2.3 Biweekly
  6. 2.3 Long-acting DPP-4 Inhibitor Drug by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 Hospital
  9. 2.3.3 Clinic
  10. 2.3.4 Others
  11. 2.4 Assumptions and Limitations
3 Long-acting DPP-4 Inhibitor Drug Breakdown Data by Type
  1. 3.1 Global Long-acting DPP-4 Inhibitor Drug Historic Market Size by Type (2021-2026)
  2. 3.2 Global Long-acting DPP-4 Inhibitor Drug Forecasted Market Size by Type (2027-2032)
4 Long-acting DPP-4 Inhibitor Drug Breakdown Data by Application
  1. 4.1 Global Long-acting DPP-4 Inhibitor Drug Historic Market Size by Application (2021-2026)
  2. 4.2 Global Long-acting DPP-4 Inhibitor Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Long-acting DPP-4 Inhibitor Drug Market Perspective (2021-2032)
  2. 5.2 Global Long-acting DPP-4 Inhibitor Drug Growth Trends by Region
  3. 5.2.1 Global Long-acting DPP-4 Inhibitor Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Long-acting DPP-4 Inhibitor Drug Historic Market Size by Region (2021-2026)
  5. 5.2.3 Long-acting DPP-4 Inhibitor Drug Forecasted Market Size by Region (2027-2032)
  6. 5.3 Long-acting DPP-4 Inhibitor Drug Market Dynamics
  7. 5.3.1 Long-acting DPP-4 Inhibitor Drug Industry Trends
  8. 5.3.2 Long-acting DPP-4 Inhibitor Drug Market Drivers
  9. 5.3.3 Long-acting DPP-4 Inhibitor Drug Market Challenges
  10. 5.3.4 Long-acting DPP-4 Inhibitor Drug Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Long-acting DPP-4 Inhibitor Drug Players by Revenue
  2. 6.1.1 Global Top Long-acting DPP-4 Inhibitor Drug Players by Revenue (2021-2026)
  3. 6.1.2 Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Long-acting DPP-4 Inhibitor Drug Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Long-acting DPP-4 Inhibitor Drug Head Office and Area Served
  6. 6.4 Global Long-acting DPP-4 Inhibitor Drug Players, Product Type & Application
  7. 6.5 Global Long-acting DPP-4 Inhibitor Drug Manufacturers Established Date
  8. 6.6 Global Long-acting DPP-4 Inhibitor Drug Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Long-acting DPP-4 Inhibitor Drug Market Size (2021-2032)
  2. 7.2 North America Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2021-2026)
  4. 7.4 North America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Long-acting DPP-4 Inhibitor Drug Market Size (2021-2032)
  2. 8.2 Europe Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Long-acting DPP-4 Inhibitor Drug Market Size by Country (2021-2026)
  4. 8.4 Europe Long-acting DPP-4 Inhibitor Drug Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Size (2021-2032)
  2. 9.2 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Long-acting DPP-4 Inhibitor Drug Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Long-acting DPP-4 Inhibitor Drug Market Size (2021-2032)
  2. 10.2 South America Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2021-2026)
  4. 10.4 South America Long-acting DPP-4 Inhibitor Drug Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Size (2021-2032)
  2. 11.2 Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Long-acting DPP-4 Inhibitor Drug Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Easton Biopharmaceuticals
  2. 12.1.1 Easton Biopharmaceuticals Company Information
  3. 12.1.2 Easton Biopharmaceuticals Business Overview
  4. 12.1.3 Easton Biopharmaceuticals Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026)
  5. 12.1.4 Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Product Portfolio
  6. 12.1.5 Easton Biopharmaceuticals Recent Developments
  7. 12.2 Takeda Pharmaceutical
  8. 12.2.1 Takeda Pharmaceutical Company Information
  9. 12.2.2 Takeda Pharmaceutical Business Overview
  10. 12.2.3 Takeda Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026)
  11. 12.2.4 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  12. 12.2.5 Takeda Pharmaceutical Recent Developments
  13. 12.3 Merck & Co
  14. 12.3.1 Merck & Co Company Information
  15. 12.3.2 Merck & Co Business Overview
  16. 12.3.3 Merck & Co Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026)
  17. 12.3.4 Merck & Co Long-acting DPP-4 Inhibitor Drug Product Portfolio
  18. 12.3.5 Merck & Co Recent Developments
  19. 12.4 Kelun Pharmaceutical
  20. 12.4.1 Kelun Pharmaceutical Company Information
  21. 12.4.2 Kelun Pharmaceutical Business Overview
  22. 12.4.3 Kelun Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026)
  23. 12.4.4 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  24. 12.4.5 Kelun Pharmaceutical Recent Developments
  25. 12.5 Haisco Pharmaceutical
  26. 12.5.1 Haisco Pharmaceutical Company Information
  27. 12.5.2 Haisco Pharmaceutical Business Overview
  28. 12.5.3 Haisco Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026)
  29. 12.5.4 Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  30. 12.5.5 Haisco Pharmaceutical Recent Developments
  31. 12.6 Beacon Pharma
  32. 12.6.1 Beacon Pharma Company Information
  33. 12.6.2 Beacon Pharma Business Overview
  34. 12.6.3 Beacon Pharma Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026)
  35. 12.6.4 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Product Portfolio
  36. 12.6.5 Beacon Pharma Recent Developments
  37. 12.7 Baiji Dichang Pharmaceutical
  38. 12.7.1 Baiji Dichang Pharmaceutical Company Information
  39. 12.7.2 Baiji Dichang Pharmaceutical Business Overview
  40. 12.7.3 Baiji Dichang Pharmaceutical Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026)
  41. 12.7.4 Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  42. 12.7.5 Baiji Dichang Pharmaceutical Recent Developments
  43. 12.8 Furiex
  44. 12.8.1 Furiex Company Information
  45. 12.8.2 Furiex Business Overview
  46. 12.8.3 Furiex Revenue in Long-acting DPP-4 Inhibitor Drug Business (2021-2026)
  47. 12.8.4 Furiex Long-acting DPP-4 Inhibitor Drug Product Portfolio
  48. 12.8.5 Furiex Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst